메뉴 건너뛰기




Volumn 18, Issue 8, 2012, Pages

Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: A mechanistic explanation for ipilimumab-induced severe enterocolitis?

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INFLIXIMAB; IPILIMUMAB; METHYLPREDNISOLONE; TRANSCRIPTION FACTOR FOXP3;

EID: 84863987094     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21927     Document Type: Letter
Times cited : (26)

References (10)
  • 1
    • 79959772576 scopus 로고    scopus 로고
    • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    • Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364: 2517-2526.
    • (2011) N Engl J Med. , vol.364 , pp. 2517-2526
    • Robert, C.1    Thomas, L.2    Bondarenko, I.3
  • 2
    • 78650428877 scopus 로고    scopus 로고
    • Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma
    • Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immunity. 2010; 10: 1-10.
    • (2010) Cancer Immunity. , vol.10 , pp. 1-10
    • Berman, D.1    Parker, S.M.2    Siegel, J.3
  • 3
    • 0030966217 scopus 로고    scopus 로고
    • Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement
    • Perez VL, Van Parijs L, Biuckians A, et al. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 1997; 6: 411-417
    • (1997) Immunity. , vol.6 , pp. 411-417
    • Perez, V.L.1    Van Parijs, L.2    Biuckians, A.3
  • 4
    • 34247643866 scopus 로고    scopus 로고
    • CTLA-4 differentially regulates the immunological synapse in CD4 T cell subsets
    • Jackman RP, Balamuth F, Bottomly K, et al. CTLA-4 differentially regulates the immunological synapse in CD4 T cell subsets. J Immunol. 2007; 178: 5543-5551.
    • (2007) J Immunol. , vol.178 , pp. 5543-5551
    • Jackman, R.P.1    Balamuth, F.2    Bottomly, K.3
  • 6
    • 37349072460 scopus 로고    scopus 로고
    • Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
    • Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007; 30: 825-830.
    • (2007) J Immunother. , vol.30 , pp. 825-830
    • Yang, J.C.1    Hughes, M.2    Kammula, U.3
  • 7
    • 78650080500 scopus 로고    scopus 로고
    • Therapy with anti-TNFa antibody enhances number and function of Foxp3+ regulatory T cells in inflammatory bowel diseases
    • Boschetti G, Nancey S, Sardi F, et al. Therapy with anti-TNFa antibody enhances number and function of Foxp3+ regulatory T cells in inflammatory bowel diseases. Inflamm Bowel Dis. 2011; 17: 160-170.
    • (2011) Inflamm Bowel Dis. , vol.17 , pp. 160-170
    • Boschetti, G.1    Nancey, S.2    Sardi, F.3
  • 8
    • 78249240373 scopus 로고    scopus 로고
    • Peripheral regulatory T cells and serum transforming growth factor-β: Relationship with clinical response to infliximab in Crohn's disease
    • Di Sabatino A, Biancheri P, Piconese S, et al. Peripheral regulatory T cells and serum transforming growth factor-β: relationship with clinical response to infliximab in Crohn's disease. Inflamm Bowel Dis. 2010; 16: 1891-1897.
    • (2010) Inflamm Bowel Dis. , vol.16 , pp. 1891-1897
    • Di Sabatino, A.1    Biancheri, P.2    Piconese, S.3
  • 9
    • 77955747724 scopus 로고    scopus 로고
    • Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab
    • Li Z, Arijs I, De Hertogh G, et al. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis. 2010; 16: 1299-1310.
    • (2010) Inflamm Bowel Dis. , vol.16 , pp. 1299-1310
    • Li, Z.1    Arijs, I.2    De Hertogh, G.3
  • 10
    • 84856769074 scopus 로고    scopus 로고
    • Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis
    • Callahan MK, Yang A, Tandon S, et al. Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. J Clin Oncol. 2011; 29 (Abstract 2505).
    • (2011) J Clin Oncol. , vol.29
    • Callahan, M.K.1    Yang, A.2    Tandon, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.